Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 10/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23375125 | 0.92 | NR1H4 (0.40) | NR1H4PPARGPPARDPPARAALDH1A1 | |
| SCHEMBL23375133 | 0.92 | NR1H4 (0.42) | NR1H4PPARGPPARDPPARASLC10A2 | |
| SCHEMBL23493374 | 0.91 | NR1H4 (0.43) | NR1H4SLC10A2ALDH1A1 | |
| SCHEMBL23375108 | 0.91 | NR1H4 (0.49) | NR1H4SLC10A2ALDH1A1 | |
| SCHEMBL23375160 | 0.90 | NR1H4 (0.44) | NR1H4SLC10A2ALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL23375183 | 0.88 | NR1H4 (0.48) | NR1H4SLC10A2ALDH1A1 | |
| SCHEMBL23375118 | 0.87 | NR1H4 (0.43) | NR1H4SLC10A2ALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL23375131 | 0.85 | NR1H4 (0.41) | NR1H4PPARGPPARDPPARASLC10A2 | |
| SCHEMBL23481668 | 0.85 | PPARD (0.36) | NR1H4PPARGPPARDPPARAALDH1A1 | |
| SCHEMBL23375145 | 0.84 | NR1H4 (0.41) | NR1H4SLC10A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-09-30 | — | — | US | disclosed |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-09-30 | — | — | US | disclosed |
| WO-2021110887-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | disclosed |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | US | disclosed |
| WO-2021110887-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2021-06-10 | — | — | WO | disclosed |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2021-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024495-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PPARG 308/4885PPARD 299/4885 |
| US-20210171479-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PPARG 308/4885PPARD 302/4885 |
| US-20210299141-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PPARG 308/4885PPARD 299/4885 |
| US-11014898-B1 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | NR1H4 6/4885PPARG 308/4885PPARD 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.